F-18-Fluorothymidine PET Is a Potential Predictive Imaging Biomarker of the Response to Gemcitabine-Based Chemotherapeutic Treatment for Recurrent Ovarian Cancer Preliminary Results in Three Patients

作者：Tsuyoshi Hideaki^*; Morishita Fumiko; Orisaka Makoto; Okazawa Hidehiko; Yoshida Yoshio

来源：Clinical Nuclear Medicine, 2013, 38(7): 560-563.

DOI：10.1097/RLU.0b013e318292ee9c

• recurrent ovarian cancer
• gemcitabine
• F-18-fluorothymidine PET
• treatment response

In order to establish early and precise methods for evaluating the effect of secondary chemotherapy in patients with recurrent ovarian cancer, both the clinical course of 3 women treated with gemcitabine-based secondary chemotherapy and the potential for early and accurate evaluation of the secondary chemotherapeutic effect of F-18-fluorothymidine (FLT) PET are reported. Standard uptake value with FLT PET decreased earlier than with F-18-fluorodeoxyglucose PET and was better correlated with a reduction in size as measured by CT. FLT PET could become a new standard for monitoring response to gemcitabine-based secondary chemotherapy treatment for recurrent ovarian cancer.

• 出版日期2013-7